Business Wire

FIND Collaborates with SpeeDx and QuantuMDx

Share

SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. The collaborative project will assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). SpeeDx will use their proprietary Plex PCR® technology to develop multiplex tests for common STIs, including gonorrhoea and Mycoplasma genitalium (Mgen), to be run on the QuantuMDx Q-POCTM POC device.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005350/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SpeeDx and QuantuMDx collaborate to assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). (Photo: Business Wire)

“We are excited by this collaboration with QuantuMDx and the potential to expand access to high quality testing options to the areas of the world that really need it,” said Dr. Elisa Mokany, SpeeDx Founder and Chief Technology Officer. “Patients around the globe are already benefiting from the clinically relevant information provided by SpeeDx tests, but we are cognisant that the current platforms and processes in use to run these tests do not readily translate to all regions of the world.”

The QuantuMDx Q-POCTM is a battery-operated, microfluidics based, sample-to-answer system for low-cost molecular testing using rapid PCR followed by microarray detection.

“QuantuMDx is always looking to expand the portfolio of diagnostic tests available on the Q-POCTM platform, and this collaboration with SpeeDx is an obvious choice given the proven compatibility of their robust chemistry across a range of platform technologies” said Jonathan O’Halloran, Chief Scientific Officer at QuantuMDx Group. “We have a common goal to enhance the standard of healthcare around the globe, this partnership will accelerate our efforts and combine our lab-standard point of care device with SpeeDx world-class test technology.”

SpeeDx has commercialised a range of tests, principally for sexually transmitted infections, that are in use across Europe, Australia and New Zealand. The flagship Resistance Plus® tests for Mgen and gonorrhoea that include markers for antibiotic resistance/susceptibility have shaped patient management guidelines around the world, providing Resistance Guided Therapy options to clinicians and enabling improved care for patients while fostering antimicrobial stewardship. Resistance Plus® GC recently received FDA Breakthrough designation to accelerate the process towards clearance for use in the U.S., and clinical trials for Resistance Plus® MG are nearing completion with expected U.S. launch early 2020.

About SpeeDx

SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com

About QuantuMDx Group

QuantuMDx Group is a multinational company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. The company’s flagship device, Q-POC™, is a next generation DNA analyser which delivers the full power of a molecular diagnostics lab in an affordable, simple-to-use, portable, desktop system. Q-POC™ offers true sample collection-to-answer analysis in minutes, in decentralized settings. Headquartered in the UK, QuantuMDx has operations and strategic partnerships in the United States, Asia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com: https://quantumdx.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SpeeDx
Europe, Australia, New Zealand
Madeline O’Donoghue
madelineo@speedx.com.au
+61 2 9209 4170

United States
Rick Roose
roi.roose@gmail.com
+1 415 202 4445

QuantuMDx
Debra Daglish
Debra.daglish@quantumdx.com
+ 44 870 803 1234

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Amit Roy Appointed to Spearhead Newly Launched Global Phosphorus Institute16.6.2021 09:00:00 CEST | Press release

The newly launched Global Phosphorus Institute (GPI) announced today the appointment of Dr. Amit Roy as Executive Director to develop and lead the Institute. His initial focus will be creating the Consortium for cutting-edge phosphorus research projects, building global coalitions, and establishing research hubs around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005021/en/ Amit Roy - Executive Director of the GPI (Photo: AETOSWire) “We are pleased that Amit joins GPI to direct this new global initiative,” said Hicham El Habti, the President of Mohammed VI Polytechnic University, Morocco (UM6P) and President of the GPI. “His vast experience combined with his enormous breadth of knowledge, research work and experience in managing the International Fertilizer Development Center are valuable assets to GPI. I am confident that his qualifications will make him succeed in building out this Institute” Amit Roy ha

BehavioSec Granted U.S. Patents for Mobile Authentication and Social Engineering Detection16.6.2021 09:00:00 CEST | Press release

BehavioSec, the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced the successful grant of two additional U.S. patents for its innovative method of verifying user identity and detecting fraud. Since its 2008 founding, BehavioSec has successfully been granted 24 U.S. patents, demonstrating the company’s continual commitment to the innovation and development of behavioral biometrics technology. With this new addition to their patent portfolio, BehavioSec technology can better protect digital identities and consumers on mobile devices from increasingly sophisticated, social engineering attacks – helping stop fraud before the damage is done. Today, BehavioSec already protects over 180 million people and 20 billion annual transactions across the globe. But as mobile devices continue to increase as a means of conducting financial transactions and accessing account information, consumers and institutions are often trading security a

Brains Bioceutical Corp. Completes a USD $31.9 Million Capital Raise with Lead Investor DSM Venturing16.6.2021 08:00:00 CEST | Press release

Brains Bioceutical Corp. (“Brains” or the “Company”) is pleased to announce the completion of a USD $31.9 million capital raise with DSM Venturing and existing Brains shareholders. DSM Venturing, who acted as lead investor in this round, is the corporate venture arm of Royal DSM (“DSM”), a global, purpose led science-based company active in health, nutrition and sustainable living. This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. Del Morgan & Co. acted as Brains’ financial agent in respect to the capital raise. “The completion of the capital raise marks an exciting milestone for the Brains’ team. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains' CEO & Chairman Rick Brar. “The growing demand for isolated CBD Active Pharmaceutical Ingredients (API’s) within the pharmaceutical and nutraceutical i

Kalray Unveils Its K200-LP Latest Acceleration Card for Data Centers16.6.2021 07:30:00 CEST | Press release

Kalray (Euronext Growth Paris: ALKAL), a leading provider in the new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, today unveils its new K200-LP™ acceleration card. K200-LP™ is a new member of Kalray’s fully programmable multi-purpose acceleration card family, based on its unique MPPA® processor, and offering an unprecedented level of performance and targeting the booming NVMe based storage market as its first implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615006166/en/ Kalray's K200-LP Acceleration Card (Photo: Kalray) The explosion of data, driven by demanding services and applications using AI and data analytics, is putting a lot of pressure on Cloud and Edge Data Center’s networking and storage to feed the demanding compute intensive resources. The primary needs are to reduce latency, enhance bandwidth and IOPs1 performance as well as offloading host CPUs, at b

Wipro joins World Economic Forum’s Partnership for New Work Standards initiative16.6.2021 07:03:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has joined the World Economic Forum’s Partnership for New Work Standards initiative to establish a healthy, resilient and equitable future of work. This initiative aims to co-create new frameworks, shape forward-thinking people policies and utilize tools and technologies to collectively build human-first work standards, with people at the heart of business. Saurabh Govil, President and Chief Human Resources Officer, Wipro Limited, said, “Companies around the world today are reinventing themselves so they can offer better employee flexibility, stability and security. Wipro is committed to advancing work standards for improved job quality, employee safety, and overall employee well-being. As we join the World Economic Forum’s Partnership for New Work Standards initiative, we hope to contribute to global discussions and beha

Luminary Launches New Subscription Channel on Apple Podcasts15.6.2021 21:27:00 CEST | Press release

Luminary, a subscription podcast network, today launched a new channel on Apple Podcasts, making all Luminary Original podcasts available globally to Apple Podcasts listeners in more than 170 countries. “We’re thrilled to collaborate with Apple, the house that built podcasting, to bring our original content to millions of listeners across the world,” said Simon Sutton, Luminary CEO. “When we founded Luminary, we believed that supporting premium subscription podcast content was important to listeners and creators alike. Distributing our content on Apple Podcasts is a critical step in fulfilling our vision,” said Matt Sacks, Luminary Co-founder and Executive Chairman. The Luminary channel includes more than 30 Luminary Original podcasts including Under the Skin with Russell Brand, Snap Judgment Presents: Spooked, The C-Word with Lena Dunham, and Leon Neyfakh’s Fiasco. The Luminary channel also includes access to The Midnight Miracle, a new show from creators Talib Kweli, yasiin bey, and

Pony.ai Becomes First Company to Test Driverless Vehicles on Public Roads in Both the U.S. and China15.6.2021 21:00:00 CEST | Press release

Silicon Valley-based Pony.ai, a leading autonomous driving company, today announced that it has begun regular and daily fully driverless testing on public roads in Fremont and Milpitas, CA. Along with the recent launch of fully driverless testing in Guangzhou, China, the company has become the first to get fully driverless automated vehicles on public roads in three cities across the world's two most dynamic mobility markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005458/en/ The successful kick-off is authorized by the previously announced driverless permit received from the California Department of Motor Vehicles for a fleet of six driverless vehicles, facilitating the total operational coverage over 100 square kilometers. Countless stealth technology iterations and numerous driverless readiness evaluations executed by a top-notch team have reinforced this significant milestone. As U.S. cities reopen in phases